Next Article in Journal / Special Issue
Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer
Previous Article in Journal / Special Issue
Dendrimers-Based Drug Delivery System: A Novel Approach in Addressing Parkinson’s Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Future Pharmacology
Volume 2
Issue 4
10.3390/futurepharmacol2040028
futurepharmacol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer

by
Amal Kamal Abdel-Aziz
1,2,3,*,
Mona Kamal Saadeldin
1,4,
Ahmed Hamed Salem
5,6,
Safaa A. Ibrahim
7,8,
Samia Shouman
9,
Ashraf B. Abdel-Naim
10 and
Roberto Orecchia
11
1
Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20139 Milan, Italy
2
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt
3
KAUST Smart-Health Initiative and Biological and Environmental Science and Engineering (BESE) Division, King Abdullah University of Science and Technology (KAUST), Jeddah 23955, Saudi Arabia
4
Electrical Engineering and Biological Sciences Departments, University of Notre Dame, Notre Dame, IN 46556, USA
5
Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
6
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt
7
Department of Microbiology and Immunology, Chicago Medical School, North Chicago, IL 60064, USA
8
Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
9
Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
10
Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
11
Scientific Directorate, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Future Pharmacol. 2022, 2(4), 431-443; https://doi.org/10.3390/futurepharmacol2040028
Submission received: 27 September 2022 / Revised: 13 October 2022 / Accepted: 13 October 2022 / Published: 18 October 2022
(This article belongs to the Special Issue Feature Papers in Future Pharmacology)
Review Reports Versions Notes

Abstract

Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used to treat malaria and autoimmune diseases for more than 70 years; they also have immunomodulatory and anticancer effects, which are linked to autophagy and autophagy-independent mechanisms. Herein, we review the pharmacokinetics, preclinical studies and clinical trials investigating the use of CQ and HCQ as adjuvant agents in cancer therapy. We also discuss their safety profile, drug–drug and drug–disease interactions. Systematic studies are required to define the use of CQ/HCQ and/or their analogues in cancer treatment and to identify predictive biomarkers of responder subpopulations.
Keywords: autophagy; chloroquine; hydroxychloroquine; cancer; pharmacokinetic; toxicity; repositioning autophagy; chloroquine; hydroxychloroquine; cancer; pharmacokinetic; toxicity; repositioning

Share and Cite

MDPI and ACS Style

Abdel-Aziz, A.K.; Saadeldin, M.K.; Salem, A.H.; Ibrahim, S.A.; Shouman, S.; Abdel-Naim, A.B.; Orecchia, R. A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer. Future Pharmacol. 2022, 2, 431-443. https://doi.org/10.3390/futurepharmacol2040028

AMA Style

Abdel-Aziz AK, Saadeldin MK, Salem AH, Ibrahim SA, Shouman S, Abdel-Naim AB, Orecchia R. A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer. Future Pharmacology. 2022; 2(4):431-443. https://doi.org/10.3390/futurepharmacol2040028

Chicago/Turabian Style

Abdel-Aziz, Amal Kamal, Mona Kamal Saadeldin, Ahmed Hamed Salem, Safaa A. Ibrahim, Samia Shouman, Ashraf B. Abdel-Naim, and Roberto Orecchia. 2022. "A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer" Future Pharmacology 2, no. 4: 431-443. https://doi.org/10.3390/futurepharmacol2040028

APA Style

Abdel-Aziz, A. K., Saadeldin, M. K., Salem, A. H., Ibrahim, S. A., Shouman, S., Abdel-Naim, A. B., & Orecchia, R. (2022). A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer. Future Pharmacology, 2(4), 431-443. https://doi.org/10.3390/futurepharmacol2040028

Article Metrics

Back to TopTop